Alzheimer’s is a cognitive disorder that affects millions of people worldwide. So far, there has been no definitive cure for it. However, a recent study shows that a new experimental medication BAN2401 may have some promise for future treatment.
The results were presented at the 2018 Alzheimer’s Association International Conference. During an 18-month trial, patients who were on the highest dose of the drug had a big reduction of beta-amyloid plaques in their brain.
Beta-amyloid is a signature symptom, and potential cause, of Alzheimer’s. It’s been thought that clearing the brain of these plaques could lead to symptom reduction. Indeed, the patients who were on higher doses of the medicine showed less of a decline in mental function compared to the placebo group.
These results have been published with cautious optimism. It is still unclear if the reductions of beta-amyloid plaques shown in the study result in meaningful benefits for patients.
Alzheimer’s Association International Conference (AAIC) 2018. Abstract 27531, presented July 25, 2018.